Orbimed Advisors - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 78 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Orbimed Advisors ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q1 2020$6,870,000
+323.8%
2,525,654
+87.0%
0.12%
+400.0%
Q4 2019$1,621,000
-20.5%
1,350,6550.0%0.02%
-41.0%
Q3 2019$2,039,000
-62.4%
1,350,6550.0%0.04%
-53.6%
Q2 2019$5,430,000
-6.5%
1,350,6550.0%0.08%
-6.7%
Q1 2019$5,808,000
-25.2%
1,350,6550.0%0.09%
-37.5%
Q4 2018$7,766,000
-14.1%
1,350,655
+102.6%
0.14%
+32.1%
Q3 2018$9,039,000
+14.2%
666,5930.0%0.11%
+16.0%
Q2 2018$7,912,000
-18.7%
666,593
-23.1%
0.09%
-22.3%
Q1 2018$9,732,000
-23.9%
866,593
-54.7%
0.12%
-25.3%
Q4 2017$12,790,000
-18.4%
1,914,6600.0%0.16%
+8.0%
Q3 2017$15,681,000
+82.4%
1,914,6600.0%0.15%
+66.7%
Q2 2017$8,597,000
-18.5%
1,914,6600.0%0.09%
-25.0%
Q1 2017$10,550,000
+259.7%
1,914,660
+164.4%
0.12%
+224.3%
Q4 2016$2,933,000
-42.5%
724,1840.0%0.04%
-36.2%
Q3 2016$5,105,000
-13.5%
724,1840.0%0.06%
-6.5%
Q2 2016$5,902,000
+65.5%
724,184
+65.0%
0.06%
+63.2%
Q1 2016$3,567,000
-32.6%
438,7840.0%0.04%
-20.8%
Q4 2015$5,292,000
+150.6%
438,784
+148.6%
0.05%
+128.6%
Q3 2015$2,112,000
-97.4%
176,470
-96.0%
0.02%
-96.5%
Q2 2015$80,857,0004,411,1860.59%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q3 2023
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$2,341,0003.33%
Matrix Capital Management Company, LP 38,974,185$66,256,0001.50%
NEA Management Company, LLC 17,082,612$29,040,0001.49%
Endurant Capital Management LP 1,824,065$3,101,0001.09%
Long Focus Capital Management, LLC 4,679,491$7,955,0000.83%
Key Client Fiduciary Advisors, LLC 416,166$707,0000.69%
PFM Health Sciences, LP 9,109,780$15,487,0000.59%
ACT CAPITAL MANAGEMENT, LLC 90,000$153,0000.21%
DAFNA Capital Management LLC 351,064$597,0000.16%
Rock Springs Capital Management LP 2,357,544$4,008,0000.12%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders